Therma Bright got a Patent for Applying Topical Treatments: USPTO

The maker of the smart-enabled AcuVidTM COVID-19 Rapid Antigen Saliva Test and other cutting-edge diagnostic and medical device technologies is pleased to announce that on February 4, 2022, the United States Patent and Trademark Office approved a U.S. patent application (U.S. 15/787,599)?

It covers a device that may apply heat and antimicrobial treatment through a detachable applicator surface of a light source.?

Therma Bright's InterceptCSTM Cold Sore Prevention Device and TherOZapTM Insect Bite Relief Device are both covered by this U.S. patent.

This heat and antimicrobial treatment technology are coupled to prevent cold sores in the InterceptCSTM device.?

TherOZapTM is a therapy device that seeks to minimize the inflammatory response, alleviating the pain, irritation, and inflammation associated with insect bites and stings.?

Furthermore, as previously announced in press releases, the Company commissioned a top Virology Research Laboratory in Canada to investigate the TherOZapTM technology's capacity to inactivate live Zika virus in culture media and restrict Zika virus ("ZIKV") proliferation in cell cultures.

"This is fantastic news for Therma Bright and our TherOZapTM Insect Relief and InterceptCSTM Cold Sore Prevention Devices," said Rob Fia, the Company's CEO. "As we continue to translate innovation into wellness, this allows us to file a U.S. Patent Application, which further safeguards our valuable intellectual property (I.P.)."

Both devices are now undergoing design revisions, and Therma Bright intends to complete prototyping in Q2. In addition, the Company expects to continue its study on Zika and other mosquito-borne diseases using the new TherOZapTM design in 2022.

Therma Bright is a forward-thinking medical diagnostic and device technology company dedicated to providing consumers and medical professionals with high-quality, cutting-edge solutions that address today's most pressing medical and healthcare issues.?

The first breakthrough unique technology developed by the Company provides effective, non-invasive, and pain-free skincare.?

The FDA granted Therma Bright Class II medical device designation for its platform technology, intended to relieve the pain, discomfort, and inflammation associated with various insect bites or stings. The FDA granted the Company permission to make the claims mentioned above in 1997.

Statements With A Future Perspective

Some of the claims in this news release are "forward-looking" statements. As mentioned in the news release, these statements refer to future events such as the development and commercialization of a quick COVID-19 viral assay and accompanying apparatus, regulatory applications, and manufacturing scale-up.?

All forward-looking statements in this press release are subject to risks and uncertainties that could cause actual results to differ from those expressed or indicated.

They will not always be reliable indicators of whether or not such results will be realized. Moreover, due to various factors and hazards, actual outcomes may differ considerably from those predicted.?

Although the Company's management thinks the forward-looking statements in this news release are based on reasonable assumptions about the date of this news release, the Company cannot guarantee that actual outcomes will be consistent with these forward-looking statements.

Except as required by applicable securities legislation, the Company disclaims any intention or obligation to update or change any forward-looking statements in this news release, whether due to new information, future events, or otherwise.

Notice: This blog and the information provided within it does not constitute legal advice. The information on this blog is for general reference purposes only. Your access to, use of, or reliance upon this blog or its materials does not create an attorney-client relationship. You should always consult with an attorney for specific legal advice regarding your individual situation.